Selpercatinib (Retevmo)


 CADTH recommends that Retevmo should be reimbursed by public drug plans for the treatment of rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) patients 12 years age and older with advanced or metastatic disease if certain conditions are met.
 only covered to treat whose has progressed while taking a first-line treatment, those who cannot tolerate have contraindication therapies.
 prescribed clinicians experience in management cancer, it is not given combination other anticancer drugs, price reduced.